BioCentury
ARTICLE | Clinical News

CF102: Phase II started

January 12, 2015 8:00 AM UTC

Can-Fite began a double-blind, placebo-controlled, international Phase II trial to evaluate 25 mg oral CF102 twice daily in about 78 HCC patients with Child-Pugh Class Beta cirrhosis who failed first-...